The short version of reversed-phase chromatography fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-23. Anything still debated is marked as such rather than presented as settled.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
| Property | Value | Notes |
|---|---|---|
| Typical form | Lyophilised powder | Reconstituted before use |
| Storage temperature, dry | -20 °C or below | Desiccated, protected from light |
| Purity determination | Reversed-phase HPLC | Reported as percentage of total peak area |
| Identity confirmation | Mass spectrometry | ESI or MALDI-TOF versus calculated mass |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies between suppliers |
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
The formation of the peptide bond consumes energy, which, in organisms, is derived from ATP. Peptides and proteins are chains of amino acids held together by peptide bonds (and sometimes by a few isopeptide bonds). Organisms use enzymes to produce nonribosomal peptides, and ribosomes to produce proteins via reactions that differ in details from dehydration synthesis. Some peptides, like alpha-amanitin, are called ribosomal peptides as they are made by ribosomes, but many are nonribosomal peptides as they are synthesized by specialized enzymes rather than ribosomes. For example, the tripeptide glutathione is synthesized in two steps from free amino acids, by two enzymes: glutamate–cysteine ligase (forms an isopeptide bond, which is not a peptide bond) and glutathione synthetase (forms a peptide bond).
=== Phase 3 === Fasedienol (Aloradine; AM-005; PH-94B; 4-androstadienol) – vomeropherine Soclenicant (BNC-210; IW-2143) – α7 nicotinic acetylcholine receptor negative allosteric modulator (abandoned after failed phase 3 trials. See [1].) VQW-765 (VQW765; AQW051; AQW-051; JQH481R778) – α7 nicotinic acetylcholine receptor partial agonist [2]
This looked like a declaration of war against the Catholic and monarchist majority in the Legislative Assembly, which had been elected on 28 May in a moment of panic. But the president again pretended to be playing the game of the Orléanists, as he had done in the case of the Constituent Assembly. The complementary elections of March and April 1850 resulted in an unexpected victory for the republicans which alarmed the conservative leaders, Thiers, Berryer and Montalembert. The president and the Assembly co-operated in the passage of the Loi Falloux of 15 March 1850, which again placed university instruction under the direction of the Church. A conservative electoral law was passed on 31 May. It required each voter to prove three years' residence at his current address by way of entries in the record of direct taxes. This effectively repealed universal suffrage: factory workers, who moved fairly often, were thus disenfranchised. The law of 16 July aggravated the severity of the press restrictions by re-establishing the "caution money" (cautionnement) deposited by proprietors and editors of papers with the government as a guarantee of good behaviour. Finally, an interpretation of the law on clubs and political societies suppressed about this time all the republican societies.
Sources: en.wikipedia.org
== Health == Domestic kittens in developed societies are usually vaccinated against common illnesses from two to three months of age. The usual combination vaccination protects against feline viral rhinotracheitis (FVR), feline calicivirus (C), and feline panleukopenia (P). This FVRCP inoculation is usually given at eight, twelve, and sixteen weeks, and an inoculation against rabies may be given at sixteen weeks. Kittens are usually spayed or neutered at seven months of age, but kittens may be neutered as young as seven weeks (if large enough), especially in animal shelters. Such early neutering does not appear to have any long-term health risks for cats, and it may even be beneficial in male cats. Kittens are commonly given deworming treatments for roundworms from about four weeks.
=== EC 2.8.2: Sulfotransferases === EC 2.8.2.1: aryl sulfotransferase EC 2.8.2.2: alcohol sulfotransferase EC 2.8.2.3: amine sulfotransferase EC 2.8.2.4: estrone sulfotransferase EC 2.8.2.5: chondroitin 4-sulfotransferase EC 2.8.2.6: choline sulfotransferase EC 2.8.2.7: UDP-N-acetylgalactosamine-4-sulfate sulfotransferase EC 2.8.2.8: [heparan sulfate]-glucosamine N-sulfotransferase EC 2.8.2.9: tyrosine-ester sulfotransferase EC 2.8.2.10: Renilla-luciferin sulfotransferase EC 2.8.2.11: galactosylceramide sulfotransferase EC 2.8.2.12: deleted, identical to EC 2.8.2.8, [heparan sulfate]-glucosamine N-sulfotransferase EC 2.8.2.13: psychosine sulfotransferase EC 2.8.2.14: bile salt sulfotransferase EC 2.8.2.15: steroid sulfotransferase EC 2.8.2.16: thiol sulfotransferase EC 2.8.2.17: chondroitin 6-sulfotransferase EC 2.8.2.18: cortisol sulfotransferase EC 2.8.2.19: triglucosylalkylacylglycerol sulfotransferase EC 2.8.2.20: protein-tyrosine sulfotransferase EC 2.8.2.21: keratan sulfotransferase EC 2.8.2.22: aryl-sulfate sulfotransferase EC 2.8.2.23: [heparan sulfate]-glucosamine 3-sulfotransferase 1 EC 2.8.2.24: desulfoglucosinolate sulfotransferase EC 2.8.2.25: flavonol 3-sulfotransferase EC 2.8.2.26: quercetin-3-sulfate 3′-sulfotransferase EC 2.8.2.27: quercetin-3-sulfate 4′-sulfotransferase EC 2.8.2.28: quercetin-3,3′-bissulfate 7-sulfotransferase EC 2.8.2.29: [heparan sulfate]-glucosamine 3-sulfotransferase 2 EC 2.8.2.30: [heparan sulfate]-glucosamine 3-sulfotransferase 3 EC 2.8.2.31: petromyzonol sulfotransferase EC 2.8.2.32: scymnol sulfotransferase EC 2.8.2.33: N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase EC 2.8.2.34: glycochenodeoxycholate sulfotransferase EC 2.8.2.35: dermatan 4-sulfotransferase EC 2.8.2.36: desulfo-A47934 sulfotransferase EC 2.8.2.37: trehalose 2-sulfotransferase EC 2.8.2.38: aliphatic desulfoglucosinolate sulfotransferase EC 2.8.2.39: hydroxyjasmonate sulfotransferase EC 2.8.2.40: ω-hydroxy-β-dihydromenaquinone-9 sulfotransferase
== Restraint generation == In order to make structure calculations, a number of experimentally determined restraints have to be generated. These fall into different categories; the most widely used are distance restraints and angle restraints.
Sources: en.wikipedia.org
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.
Synthesis routes, purification steps and the analytical method used all affect the reported figure. A purity number is only comparable when the chromatographic conditions and detection wavelength are stated.
It reports what the supplier measured on a sample, which is useful but not absolute. Independent mass confirmation on the received lot is the more reliable check.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.